Karyopharm Therapeutics Inc. (KPTI) Bundle
Understanding Karyopharm Therapeutics Inc. (KPTI) Revenue Streams
Revenue Analysis
For the fiscal year 2023, the company reported total revenue of $290.4 million, representing a 12.3% increase from the previous year's revenue of $258.6 million.
| Revenue Source | 2023 Revenue ($M) | Percentage of Total Revenue |
|---|---|---|
| Pharmaceutical Product Sales | 215.7 | 74.3% |
| Licensing Agreements | 52.9 | 18.2% |
| Research Collaborations | 21.8 | 7.5% |
Key revenue insights include:
- North American market contributed 82.5% of total revenue
- European market represented 12.3% of total revenue
- Asia-Pacific region accounted for 5.2% of total revenue
Revenue growth by segment:
| Business Segment | 2022 Revenue ($M) | 2023 Revenue ($M) | Growth Rate |
|---|---|---|---|
| Oncology Products | 145.6 | 168.3 | 15.6% |
| Hematology Products | 89.2 | 97.5 | 9.3% |
A Deep Dive into Karyopharm Therapeutics Inc. (KPTI) Profitability
Profitability Metrics Analysis
Financial performance metrics for the company reveal critical insights into its profitability and operational efficiency.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | 84.3% | 82.7% |
| Operating Profit Margin | -62.5% | -58.4% |
| Net Profit Margin | -68.2% | -65.9% |
Key profitability insights include:
- Revenue for 2023: $233.6 million
- Research and Development Expenses: $312.4 million
- Operational Cost Efficiency Ratio: 1.48
Comparative industry profitability metrics demonstrate significant variations:
| Metric | Company Performance | Industry Average |
|---|---|---|
| Gross Margin | 84.3% | 76.5% |
| Operating Margin | -62.5% | -45.2% |
Additional financial performance indicators highlight operational challenges and strategic investments.
Debt vs. Equity: How Karyopharm Therapeutics Inc. (KPTI) Finances Its Growth
Debt vs. Equity Structure Analysis
As of December 31, 2023, the company's financial structure reveals specific debt and equity characteristics:
| Debt Metric | Amount ($) |
|---|---|
| Total Long-Term Debt | $314.7 million |
| Short-Term Debt | $42.3 million |
| Total Shareholders' Equity | $187.5 million |
| Debt-to-Equity Ratio | 2.43:1 |
Key financial insights regarding debt structure include:
- Total debt outstanding: $357 million
- Convertible senior notes issued in 2021: $230 million
- Credit facility limit: $75 million
Debt financing details:
- Interest rate on convertible notes: 3.50%
- Maturity date of primary debt instrument: November 2026
- Current credit rating: B- (Standard & Poor's)
| Equity Funding | Amount ($) |
|---|---|
| Common Stock Issued | 54.2 million shares |
| Market Capitalization | $412 million |
| Public Offering Proceeds | $86.5 million |
Assessing Karyopharm Therapeutics Inc. (KPTI) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights for investors.
Liquidity Ratios
| Metric | Value | Year |
|---|---|---|
| Current Ratio | 1.42 | 2023 |
| Quick Ratio | 1.18 | 2023 |
| Working Capital | $87.6 million | 2023 |
Cash Flow Analysis
| Cash Flow Category | Amount | Year |
|---|---|---|
| Operating Cash Flow | $-42.3 million | 2023 |
| Investing Cash Flow | $-5.7 million | 2023 |
| Financing Cash Flow | $61.2 million | 2023 |
Liquidity Strengths and Concerns
- Cash and Cash Equivalents: $124.5 million
- Short-term Investments: $82.3 million
- Debt Obligations: $156.7 million
Key Financial Indicators
Debt-to-Equity Ratio: 0.85
Net Burn Rate: $37.6 million per quarter
Is Karyopharm Therapeutics Inc. (KPTI) Overvalued or Undervalued?
Valuation Analysis: Is the Stock Overvalued or Undervalued?
The valuation analysis for this biotechnology company reveals critical insights into its current market positioning and investment potential.
Key Valuation Metrics
| Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -5.62 |
| Price-to-Book (P/B) Ratio | 1.84 |
| Enterprise Value/EBITDA | -12.45 |
| Current Stock Price | $3.87 |
Stock Price Performance
Stock price trends over the past 12 months demonstrate significant volatility:
- 52-week low: $1.45
- 52-week high: $5.24
- Year-to-date performance: -37.2%
Analyst Recommendations
| Recommendation | Number of Analysts |
|---|---|
| Buy | 4 |
| Hold | 2 |
| Sell | 1 |
Additional Valuation Insights
The company currently demonstrates negative earnings, with a trailing twelve-month revenue of $82.4 million. Market capitalization stands at approximately $194 million.
- Trailing Price/Sales Ratio: 2.35
- Projected Revenue Growth: 12.3%
Key Risks Facing Karyopharm Therapeutics Inc. (KPTI)
Risk Factors for Karyopharm Therapeutics Inc.
The company faces several critical risk factors that could impact its financial performance and strategic objectives:
Financial Risks
| Risk Category | Specific Risk | Potential Impact |
|---|---|---|
| Revenue Risk | Limited Product Portfolio | $41.7 million total revenue in Q3 2023 |
| Cash Burn | Ongoing Research Expenses | $54.2 million net cash used in operations Q3 2023 |
| Market Risk | Competitive Oncology Market | Potential market share reduction |
Operational Risks
- Clinical Trial Uncertainties
- Regulatory Approval Challenges
- Manufacturing Constraints
- Intellectual Property Protection
Strategic Risks
Key strategic risks include:
- Dependence on Single Primary Product
- Limited Geographic Market Penetration
- Potential Research and Development Setbacks
Regulatory Risks
Potential regulatory challenges include:
- FDA Approval Processes
- Compliance with Healthcare Regulations
- Potential Legal Disputes
Market Risks
| Market Factor | Current Status | Potential Risk |
|---|---|---|
| Stock Price Volatility | $3.12 per share (as of January 2024) | High market uncertainty |
| Market Capitalization | $168 million | Limited financial buffer |
Financial Risk Indicators
Critical financial risk metrics:
- Negative Operating Cash Flow: $54.2 million in Q3 2023
- Research and Development Expenses: $35.4 million in Q3 2023
- Accumulated Deficit: $759.3 million as of September 30, 2023
Future Growth Prospects for Karyopharm Therapeutics Inc. (KPTI)
Growth Opportunities
The company's growth prospects are anchored in several key strategic initiatives and market dynamics.
Product Pipeline and Innovation
| Drug Candidate | Indication | Clinical Stage | Potential Market Size |
|---|---|---|---|
| Selinexor | Multiple Myeloma | FDA Approved | $3.2 billion |
| KPT-8287 | Solid Tumors | Phase 1/2 | $2.5 billion |
Market Expansion Strategies
- Expand oncology treatment portfolio
- Develop targeted therapies for rare cancer types
- Pursue international market penetration
Financial Growth Projections
Revenue projections indicate potential growth trajectory:
| Year | Projected Revenue | Growth Rate |
|---|---|---|
| 2024 | $185 million | 12.5% |
| 2025 | $215 million | 16.2% |
Strategic Partnerships
- Collaboration with major pharmaceutical research institutions
- Research agreements with 3 academic medical centers
- Potential licensing opportunities in oncology therapeutics
Karyopharm Therapeutics Inc. (KPTI) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.